Understand More. Fear Less.
A clear companion for patients and families, from unexpected bleeding to understanding a pathology report, choosing treatment and living beyond cancer. Start where you are today.
- POLEmut: qualifying pathogenic proofreading mutation
- MMRd: defective DNA mismatch repair
- p53abn: abnormal p53 biology after classifier integration
- NSMP: none of the other groups; grade and ER refine risk
Your searchable chapter index
25 chapters shown
A · Understanding endometrial cancer
Understanding Endometrial Cancer
Endometrial cancer begins in the lining of the uterus. Understanding where it starts helps make sense of bleeding, biopsy results and the treatments your team discusses.
Read chapter →CHAPTER 02Symptoms and Early Warning Signs
A change in bleeding deserves attention, even when it is painless. Most abnormal bleeding has a non-cancer cause, but assessment is the reliable way to find out.
Read chapter →CHAPTER 03Causes and Risk Factors
Risk factors can help guide prevention and investigation, but they cannot explain why one particular person develops cancer. Care should focus on support, not blame.
Read chapter →CHAPTER 04Endometrial Hyperplasia and Precancer
Hyperplasia means overgrowth of the uterine lining. The key distinction is whether abnormal cells suggest a precancerous process and whether an invasive cancer might already be present.
Read chapter →CHAPTER 05Types of Endometrial Cancer
The type and grade describe what the cancer looks like under the microscope. They help the team estimate behaviour, but need to be interpreted alongside molecular testing and stage.
Read chapter →B · Diagnosis and molecular testing
How Endometrial Cancer Is Diagnosed
Diagnosis usually requires a tissue sample. Examination and imaging help locate a problem, but they cannot reliably determine its histology or molecular group on their own.
Read chapter →CHAPTER 07Imaging and Staging Investigations
Imaging helps the team estimate local invasion and look for spread when that information may change treatment. More scans are not always better.
Read chapter →CHAPTER 08Understanding the Pathology Report
Your pathology report brings together the tissue findings that guide staging and postoperative treatment. It is normal to need a clinician to translate the terminology.
Read chapter →CHAPTER 09Molecular Classification: The Four Major Groups
Molecular classification describes biological features of the tumour. It adds information to stage and histology and can influence both postoperative treatment and treatment of advanced disease.
Read chapter →CHAPTER 10Biomarkers and Genetic Testing
Tumour biomarkers help select treatments and identify possible inherited risk. Genetic counselling explains when a finding may matter to relatives and what additional testing can establish.
Read chapter →C · Staging and treatment planning
FIGO Staging of Endometrial Cancer
FIGO 2023 combines the extent of disease with selected histological and molecular features. A stage number cannot be assigned reliably from symptoms or a scan alone.
Read chapter →CHAPTER 12How Doctors Choose Treatment
A treatment plan combines the cancer's features with your health, priorities and practical circumstances. The aim is to offer useful benefit while avoiding unnecessary harm.
Read chapter →CHAPTER 13Surgery for Endometrial Cancer
For many patients, surgery removes the cancer and establishes the information needed to decide whether further treatment is useful. The operation should be tailored to disease risk and personal health.
Read chapter →CHAPTER 14Fertility-Preserving Treatment
Preserving the uterus can be considered for a small, carefully selected group. It requires specialist assessment, repeated tissue sampling and acceptance that definitive surgery may become necessary.
Read chapter →CHAPTER 15Radiotherapy
Radiotherapy uses carefully planned radiation to treat cancer cells in a defined area. The treatment field and technique depend on whether the aim is prevention after surgery, definitive treatment or control of recurrence.
Read chapter →CHAPTER 16Chemotherapy
Chemotherapy treats cancer cells throughout the body. It may reduce recurrence risk after surgery or help control advanced disease, but many people with low-risk cancer do not need it.
Read chapter →D · Modern systemic treatments
Immunotherapy in Endometrial Cancer
Immune checkpoint inhibitors help the immune system recognize and attack cancer. They have changed treatment for advanced endometrial cancer, especially mismatch repair deficient disease.
Read chapter →CHAPTER 18Targeted Therapy and Hormonal Treatment
These treatments act on selected biological features or hormonal signals. Their usefulness depends on the tumour, previous therapy, disease tempo and the person's ability to tolerate treatment.
Read chapter →CHAPTER 19Treatment of Early-Stage Endometrial Cancer
After surgery, the central question is whether additional treatment meaningfully reduces recurrence risk. Many patients can safely avoid it, while others benefit from radiation, chemotherapy or a combination.
Read chapter →CHAPTER 20Treatment of Advanced and Metastatic Disease
Advanced disease includes several different situations. Some patients with regional spread receive curative-intent combined treatment, while others need treatment focused on durable control and quality of life.
Read chapter →CHAPTER 21Recurrent Endometrial Cancer
Recurrence means cancer has returned after treatment. The most useful first step is to establish where it is, what treatment was previously given and whether local treatment could still be curative.
Read chapter →E · Recovery, survivorship and support
Side Effects and Supportive Care
Supportive care prevents and treats the physical, emotional and practical effects of cancer. Reporting symptoms early often makes treatment safer and daily life more manageable.
Read chapter →CHAPTER 23Follow-Up, Surveillance and Recurrence Detection
Follow-up checks recovery, addresses late effects and investigates concerning symptoms. It is not simply a schedule of scans, and it should reflect recurrence risk and individual needs.
Read chapter →CHAPTER 24Prognosis, Survival and Living Beyond Cancer
Prognosis describes the likely course of a disease in a group of people with similar features. It cannot tell one person exactly what will happen.
Read chapter →CHAPTER 25Frequently Asked Questions and Patient Decision Guide
Use these answers to prepare for a conversation with your team. They explain common concerns but cannot replace review of your own reports and circumstances.
Read chapter →- Localized disease: surgery and risk-adapted additional treatment
- Selected fertility pathway: specialist supervision and repeat biopsies
- Advanced or recurrent disease: systemic and selected local treatments
- Every stage: symptom support, shared decisions and follow-up
Common first questions
Does every patient need chemotherapy?
No. Many low-risk cancers need surgery and follow-up only. Additional treatment depends on the integrated risk assessment.
Does MMR deficiency mean inherited cancer?
Not necessarily. Further testing and genetic counselling distinguish possible Lynch syndrome from acquired tumour changes.
Read all 36 questions and the patient checklistReferences and review status
- ESGO–ESTRO–ESP endometrial carcinoma guideline update, 2025
- Berek et al. FIGO staging of endometrial cancer, 2023
- ACOG updated postmenopausal bleeding guidance, April 2026
Evidence/editorial check: 30 October 2026. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.
Evidence scope and update policy